Even in an era of remarkable therapeutics for neovascular age-related macular degeneration, there remains a lack of therapies to improve vision in dry AMD.
Many patients continue to live with central vision loss that erodes independence and quality of life.
They may be “stable” anatomically, yet functionally they struggle: recognizing faces, reading mail, managing medications, cooking safely, shopping, paying bills, using a phone or navigating unfamiliar environments. For the clinician, this creates a familiar gap — patients who are doing everything “right” medically but still feel they are